CNS Correlates of Extended Sleep Restriction

Sponsor
Walter Reed Army Institute of Research (WRAIR) (U.S. Fed)
Overall Status
Not yet recruiting
CT.gov ID
NCT05547880
Collaborator
National Institute of Mental Health (NIMH) (NIH), National Intrepid Center of Excellence (U.S. Fed)
18
24

Study Details

Study Description

Brief Summary

Chronic sleep restriction is ubiquitous in both the general population and the military. The deleterious effects of sleep loss on human alertness and cognitive performance have been documented in numerous studies dating back to the nineteenth century. Over the past decade, evidence has emerged indicating that chronic sleep restriction may also precipitate deleterious, long lasting neuropathological changes in the brain. The purpose of this study is to determine neuropathological effects of sleep restriction and identify physiological mechanisms that correlate with sleep loss-induced performance impairment.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Anticipated Enrollment :
18 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
CNS Correlates of Extended Sleep Restriction
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Outcome Measures

Primary Outcome Measures

  1. Positron Emission Tomography (PET) based measurement of neuroinflammation [3 Days]

    Positron Emission Tomography (PET) is the brain imaging method and [11C]ER176 is the PET radioligand providing an index of neuroinflammation

Secondary Outcome Measures

  1. Psychomotor Vigilance Task (PVT) [55 Days]

    Measure of cognitive performance

  2. Actigraphy [55 Days]

    Activity monitoring used to infer sleep-wake patterns

  3. Polysomnographic measurements of sleep and wakefulness [19 Days]

    Measure of various aspects of sleep and wakefulness

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 39 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
  • Ages 18 to 39 (inclusive)

  • Weigh at least 140 lbs

  • A body mass index (BMI) below 30.

  • Learned English by the age of 2

  • Females must not be pregnant or nursing, and must be on some form of birth control, if sexually active (e.g., oral contraceptive, condom, intrauterine device, etc.)

  • No history of sleeping problems such as insomnia or sleep apnea.

  • Test negative for alcohol, nicotine, illegal drugs, and not take certain medications.

  • Must not excessively consume alcohol or caffeine.

  • Active duty and Federal employees must be on leave during participation.

  • No history of heart disease (high blood pressure), neurologic disorder (such as seizures of epilepsy), liver disease, kidney disease, or metabolic disorder or diabetes.

  • No history of underlying acute or chronic pulmonary disease requiring daily inhaler use.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Walter Reed Army Institute of Research (WRAIR)
  • National Institute of Mental Health (NIMH)
  • National Intrepid Center of Excellence

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Samantha Riedy, Principal Investigator, Walter Reed Army Institute of Research (WRAIR)
ClinicalTrials.gov Identifier:
NCT05547880
Other Study ID Numbers:
  • 2804
  • MO220146
First Posted:
Sep 21, 2022
Last Update Posted:
Sep 21, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Samantha Riedy, Principal Investigator, Walter Reed Army Institute of Research (WRAIR)

Study Results

No Results Posted as of Sep 21, 2022